ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
AC Immune SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 13, 2026
$2.44+0.04 (+1.88%)
Close on Oct 19, 2026
AC Immune statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | AC Immune | Industry median |
|---|---|---|
| Market Cap | CHF 205.82M | CHF 62.39M |
| Enterprise Value | CHF 179.03M | CHF 20.23M |
| PS Ratio | 57.61 |
Enterprise value
| Measure | AC Immune | Industry median |
|---|---|---|
| EV / Sales | 50.11 |
Income (trailing twelve months)
| Measure | AC Immune | Industry median |
|---|---|---|
| Revenue | CHF 3.57M | |
| Operating Income | -CHF 69.32M | -CHF 69.32M |
| Pretax Income | -CHF 70.45M | -CHF 70.45M |
| EBITDA | -CHF 69.32M | -CHF 69.32M |
| EPS (Diluted) | -0.70 CHF | -1.65 CHF |
Margins
| Measure | AC Immune | Industry median |
|---|---|---|
| Operating Margin | -1940.1% | |
| Pretax Margin | -1971.7% | |
| EBITDA Margin | -1940.1% | |
| FCF Margin | -1963.7% |
Returns
| Measure | AC Immune | Industry median |
|---|---|---|
| Return on Capital Employed (ROCE) | -116.4% | -63.8% |
Growth
| Measure | AC Immune | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -86.9% | |
| FCF Growth (YoY) | -207.5% | |
| Revenue Growth (3Y CAGR) | -3.17% | |
| Revenue Growth (5Y CAGR) | -25.4% |
Balance sheet
| Measure | AC Immune | Industry median |
|---|---|---|
| Cash & Short-Term Investments | CHF 26.80M | CHF 26.80M |
| Net Cash (Debt) | CHF 26.80M | CHF 26.80M |
| Net Cash Per Share | 0.26 CHF | 1.13 CHF |
| Working Capital | CHF 2.03M | CHF 11.40M |
Financial position
| Measure | AC Immune | Industry median |
|---|---|---|
| Current Ratio | 1.02 | 2.65 |
| Quick Ratio | 0.28 | 2.21 |
| Interest Coverage | -362.92 | -116.78 |
Cash flow (trailing twelve months)
| Measure | AC Immune | Industry median |
|---|---|---|
| Operating Cash Flow | -CHF 69.26M | -CHF 51.26M |
| Capital Expenditures | -CHF 900.00K | -CHF 446.00K |
| Free Cash Flow | -CHF 70.16M | -CHF 51.97M |
| FCF Per Share | -0.69 CHF | -1.11 CHF |
Efficiency
| Measure | AC Immune | Industry median |
|---|---|---|
| Asset Turnover | 0.02 | |
| Revenue Per Employee | CHF 29.29K | |
| Employee Count | 122 | 49 |
Dividends and yields
| Measure | AC Immune | Industry median |
|---|---|---|
| FCF Yield | -34.1% | -42.3% |
Shares
| Measure | AC Immune | Industry median |
|---|---|---|
| Shares Outstanding | 101,742,000 | 50,231,950 |
| Shares Change (YoY) | 1.06% | 20.2% |
| Float | 77,734,700 | 41,812,550 |
| Shares Held by Insiders | 23.6% | 19.3% |
Taxes
| Measure | AC Immune | Industry median |
|---|---|---|
| Income Tax | CHF 0 | CHF 0 |
Scores
| Measure | AC Immune | Industry median |
|---|---|---|
| Altman Z-Score | -4.30 | -4.30 |
Calculated by StockData from AC Immune's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.